Vasogen Inc. announces positive results in Rheumatoid Arthritis.TORONTO--(BUSINESS WIRE)--Nov. 19, 1996--Vasogen Inc., (ME:VAS; OTCBB OTCBB See OTC Bulletin Board (OTCBB). :VSOGF) today announced the results of a retrospective analysis of the effects of VasoCare(tm) therapy in 30 patients with active Rheumatoid Arthritis. The results show a statistically significant improvement in key clinical and laboratory parameters of disease activity. Rheumatoid Arthritis affects approximately four million people in North America alone. The patients, all treated and monitored by a senior physician in Essen, Germany, over a 2-15 month period, reported sustained improvement in arthritic symptoms and general well being (p<0.0001). In addition, following treatment, there were changes in key rheumatic rheu·mat·ic adj. Relating to or characterized by rheumatism. n. One who is affected by rheumatism. rheumatic pertaining to or affected with rheumatism. parameters - an approximate 50% reduction in the blood sedimentation rate (p<0.0001) and a 25% reduction in C reactive protein C reactive protein Lab medicine A 120 kD polypeptide of the pentraxin family which is produced by the liver during inflammation and detectable in serum in various conditions particularly during acute immune responses, named for its ability to bind the C levels (P<0.009), both of which are accepted as primary laboratory measures of disease activity by the American College of Rheumatology rheumatology /rheu·ma·tol·o·gy/ (-tol´ah-je) the branch of medicine dealing with rheumatic disorders, their causes, pathology, diagnosis, treatment, etc. rheu·ma·tol·o·gy n. . Blood levels of Rheumatoid Factor (p<0.02) and leucocyte leu·co·cyte n. Variant of leukocyte. leucocyte leukocyte. counts (p<0.0001), which are additional disease activity indicators, were also significantly reduced. Consistent with all clinical experience with VasoCare(tm) therapy to date, no adverse side effects were reported in connection with the treatment of this patient group. Dr. George de Veber, Vasogen's Medical Director stated, "While the results of this retrospective analysis will require confirmation in a prospective placebo controlled study, they are highly suggestive of a modulating effect of VasoCare(tm) therapy on autoimmune activity, a finding consistent with Vasogen's recent scientific research and our emerging understanding of VasoCare(tm)'s mechanism of action." "These results are an additional indication that VasoCare(tm) therapy has the ability to beneficially affect the autoimmune disorders. In view of these findings, we will be expanding our research program beyond the Company's current focus into the broader spectrum of autoimmune diseases", said David Elsley, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Vasogen Inc. Vasogen is a healthcare company dedicated to the research, development and commercialization of VasoCare(tm) therapy for the treatment of vascular disease - the leading cause of death and disability in the western world. Results to date suggest that VasoCare(tm) therapy is effective, safe and well tolerated - a profile actively sought after by all healthcare companies today. -0- NOTE TO EDITORS: Montreal Exchange Symbol: VAS, NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. Symbol: VSOGF - US Rule 12g3(b) Exemption #82 - 4372 CONTACT: Vasogen, Inc., Toronto Trevor Burns, 416/213-0126 ext 229 email investor@vasogen.com NewsOnDemand 1-800-896-1660 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion